Literature DB >> 20413859

Calretinin interneurons are early targets of extracellular amyloid-beta pathology in PS1/AbetaPP Alzheimer mice hippocampus.

David Baglietto-Vargas1, Ines Moreno-Gonzalez, Raquel Sanchez-Varo, Sebastian Jimenez, Laura Trujillo-Estrada, Elisabeth Sanchez-Mejias, Manuel Torres, Manuel Romero-Acebal, Diego Ruano, Marisa Vizuete, Javier Vitorica, Antonia Gutierrez.   

Abstract

Specific neuronal networks are preferentially affected in the early stages of Alzheimer's disease (AD). The distinct subpopulations of hippocampal inhibitory GABAergic system have been shown to display differential vulnerability to neurodegeneration in AD. We have previously reported a substantial loss of SOM/NPY interneurons, whereas those expressing parvalbumin were unaltered, in the hippocampus of 6 month-old PS1/AbetaPP transgenic mice. In the present study, we now investigated the pathological changes of hippocampal calretinin (CR) interneurons in this PS1/AbetaPP model from 2 to 12 months of age. The total number of CR-immunoreactive inhibitory cells was determined by stereology in CA1 and CA2/3 subfields. Our findings show a substantial decrease (35%-45%) of CR-positive interneurons in both hippocampal subfields of PS1/AbetaPP mice at very early age (4 months) compared to age-matched control mice. This decrease was accompanied by a reduced CR mRNA content as determined by quantitative RT-PCR. However, the number of another hippocampal CR-positive population (belonging to Cajal-Retzius cells) was not affected. The selective early loss of CR-interneurons was parallel to the appearance of extracellular Abeta deposits, preferentially in CR-axonal fields, and the formation of dystrophic neurites. This specific GABAergic subpopulation plays a crucial role in the generation of synchronous rhythmic activity in hippocampus by controlling other interneurons. Therefore, early alterations of hippocampal inhibitory functionality in AD, caused by select CR-cells neurodegeneration, could result in cognitive impairments seen in initial stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413859     DOI: 10.3233/JAD-2010-100066

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  36 in total

1.  Changes induced by natural scrapie in the calretinin-immunopositive cells and fibres of the sheep cerebellar cortex.

Authors:  Adolfo Toledano; María-Isabel Alvarez; Eva Monleón; Adolfo Toledano-Díaz; Juan-José Badiola; Marta Monzón
Journal:  Cerebellum       Date:  2012-06       Impact factor: 3.847

Review 2.  Epileptic activity in Alzheimer's disease: causes and clinical relevance.

Authors:  Keith A Vossel; Maria C Tartaglia; Haakon B Nygaard; Adam Z Zeman; Bruce L Miller
Journal:  Lancet Neurol       Date:  2017-04       Impact factor: 44.182

Review 3.  Inhibiting BACE1 to reverse synaptic dysfunctions in Alzheimer's disease.

Authors:  Riqiang Yan; Qingyuan Fan; John Zhou; Robert Vassar
Journal:  Neurosci Biobehav Rev       Date:  2016-04-01       Impact factor: 8.989

Review 4.  Hippocampal GABAergic Inhibitory Interneurons.

Authors:  Kenneth A Pelkey; Ramesh Chittajallu; Michael T Craig; Ludovic Tricoire; Jason C Wester; Chris J McBain
Journal:  Physiol Rev       Date:  2017-10-01       Impact factor: 37.312

5.  Short-term modern life-like stress exacerbates Aβ-pathology and synapse loss in 3xTg-AD mice.

Authors:  David Baglietto-Vargas; Yuncai Chen; Dongjin Suh; Rahasson R Ager; Carlos J Rodriguez-Ortiz; Rodrigo Medeiros; Kristoffer Myczek; Kim N Green; Tallie Z Baram; Frank M LaFerla
Journal:  J Neurochem       Date:  2015-07-14       Impact factor: 5.372

6.  Impact of hippocampal neuronal ablation on neurogenesis and cognition in the aged brain.

Authors:  S T Yeung; K Myczek; A P Kang; M A Chabrier; D Baglietto-Vargas; F M Laferla
Journal:  Neuroscience       Date:  2013-12-04       Impact factor: 3.590

7.  Amyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss.

Authors:  Phillip J Hsu; Haochang Shou; Tammie Benzinger; Daniel Marcus; Tony Durbin; John C Morris; Yvette I Sheline
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

8.  Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology.

Authors:  David Baglietto-Vargas; Rodrigo Medeiros; Hilda Martinez-Coria; Frank M LaFerla; Kim N Green
Journal:  Biol Psychiatry       Date:  2013-01-08       Impact factor: 13.382

9.  Hippocampal oscillatory activity in Alzheimer's disease: toward the identification of early biomarkers?

Authors:  Romain Goutagny; Slavica Krantic
Journal:  Aging Dis       Date:  2013-01-23       Impact factor: 6.745

10.  Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease.

Authors:  Heather A Born; Ji-Yoen Kim; Ricky R Savjani; Pritam Das; Yuri A Dabaghian; Qinxi Guo; Jong W Yoo; Dorothy R Schuler; John R Cirrito; Hui Zheng; Todd E Golde; Jeffrey L Noebels; Joanna L Jankowsky
Journal:  J Neurosci       Date:  2014-03-12       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.